Celldex Therapeutics’s “Buy” Rating Reaffirmed at Cantor Fitzgerald (CLDX)
Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating restated by Cantor Fitzgerald in a research note issued on Wednesday, American Banking & Market News reports. They currently have a $39.00 price objective on the stock. Cantor Fitzgerald’s price target points to a potential upside of 3.09% from the stock’s previous close.
CLDX has been the subject of a number of other recent research reports. Analysts at Oppenheimer raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) to $40.00 in a research note to investors on Wednesday. Separately, analysts at Guggenheim raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $26.00 to $34.00 in a research note to investors on Tuesday, September 24th. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $28.00 to $45.00 in a research note to investors on Monday, September 23rd. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $34.38.
Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 37.83 on Wednesday. Celldex Therapeutics has a one year low of $5.02 and a one year high of $37.98. The stock has a 50-day moving average of $25.63 and a 200-day moving average of $17.71. The company’s market cap is $3.064 billion.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.22) by $0.02. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. The company’s quarterly revenue was down 51.7% on a year-over-year basis. On average, analysts predict that Celldex Therapeutics will post $-0.97 earnings per share for the current fiscal year.
Celldex Therapeutics, Inc (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.